ClinicalTrials.gg
CompletedNCT04023994Updated Aug 9, 2021Results posted

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

A Phase 1 interventional study of RO7126209 and Placebo in Alzheimers Disease, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-09.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies in Alzheimer Disease by Hoffmann-La Roche — 3 open to participants now, 8 under way, 4 of them phase 3. Alzheimer Disease · Hoffmann-La Roche.

Enrollment
34th of 40
36 · median 247
Started
2019
with 2 others
Phase 1
13 of 40
none open now
Registered
26th of 40
by date

Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one is the 34th largest by enrollment, is one of 3 that started in 2019, is one of 13 in phase 1, and was the 26th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 40 studies in Alzheimer Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Alzheimer Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

Study BP41192 is a randomized, adaptive, placebo-controlled parallel group study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending intravenous (IV) doses of RO7126209 in healthy participants. RO7126209 is being developed for the treatment of Alzheimer's Disease.

Read the detailed description

This study uses a parallel group design, with participants recruited in 5 planned sequential cohorts. Additional cohort(s) may be added if dose escalation stopping criteria are not met after cohort 5. Participants will receive a single IV dose of either RO7126209 or placebo. RO7126209 doses will be administered in ascending order. After the starting dose, subsequent doses will be selected in an adaptive manner during study conduct based on emerging safety, tolerability and PK data.

03

Conditions studied

  • Alzheimers Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy status is defined by the absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead , ophthalmologic examination, hematology, blood chemistry, coagulation, serology, and urinalysis.
  • (BMI) of 18-30 kg/m2 inclusive
  • During the treatment period and until the final follow up visit, agreement to: (1) Remain abstinent or use measures such as a condom plus an additional contraceptive method that together result in a failure rate of \<1% per year, with a partner who is a woman of . (2) With pregnant female partner, remain abstinent or use contraceptive measures such as a condom to avoid exposing the embryo. (3) Refrain from donating sperm from Day 1 of the study until 90 days after last dose.

Exclusion criteria

Exclusion Criteria:

  • Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study.
  • History of any gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological, ophthalmologic, hematological or allergic disease, metabolic disorder, cancer or cirrhosis.
  • Any suspicion or history of alcohol abuse and/or suspicion of regular consumption of drug of abuse within the last 5 years.
  • Positive result on (HBV), (HCV), or (HIV) 1 and 2.
  • History or presence of clinically significant abnormalities or cardiovascular disease.
  • Clinically-significant abnormalities in laboratory test results.
  • Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first dose administration.
  • Impaired hepatic function as indicated by screening (AST) or alanine aminotransferase (ALT) >=1.5 x the (ULN) or abnormal total unless due to Gilbert's disease.
  • Any clinically relevant history of or allergic reactions, either spontaneous or following drug administration, or exposure to foods or environmental agents.
  • History of hypersensitivity to biologic agents or any of the in the formulation.
  • History of raised intra-cerebral pressure or vertebral joint pathology
  • Use of prohibited medication or herbal remedies as described in the section of concomitant medications
  • Prior administration of gantenerumab (RO4909832)
  • Any vaccination within two months prior to Day 1
  • Participation in an drug medicinal product or medical device study within 30 days before screening or within seven times the elimination half-life if known, whichever is longer.
  • Participants who regularly smoke more than 5 cigarettes daily or equivalent and are unable or unwilling not to smoke during the in-house period.
  • Donation or loss of blood over 500 mL within three months prior to Day 1 and donation of blood for the duration of the study until follow-up.
  • Evidence of clinically significant brain magnetic resonance imaging (MRI) findings, including lacunar infarct, territorial infarct or macroscopic hemorrhage, microbleed or area of hemosiderosis, or deep white matter lesions corresponding to an overall Fazekas score of ≥ 2.
  • Claustrophobia, presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body that would contraindicate an MRI scan.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    In Cohorts 1-5, there were ten participants in total who received placebo, two in each cohort.

    Drug: Placebo

  • Experimental
    RO7126209 (0.1 mg/kg)

    Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.1 mg/kg).

    Drug: RO7126209

  • Experimental
    RO7126209 (0.4 mg/kg)

    Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.4 mg/kg).

    Drug: RO7126209

  • Experimental
    RO7126209 (1.2 mg/kg)

    Healthy volunteers will be administered a single intravenous dose of RO7126209 (1.2 mg/kg).

    Drug: RO7126209

  • Experimental
    RO7126209 (3.6 mg/kg)

    Healthy volunteers will be administered a single intravenous dose of RO7126209 (3.6 mg/kg).

    Drug: RO7126209

  • Experimental
    RO7126209 (7.2 mg/kg)

    Healthy volunteers will be administered a single intravenous dose of RO7126209 (7.2 mg/kg).

    Drug: RO7126209

Interventions

  • Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.

  • DrugPlacebo

    Participants will be administered a single intravenous dose of matching placebo.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.

    Time frame: Up to approximately 9 weeks

Secondary outcomes

  1. Concentration at the End of Infusion (Cend) of RO7126209

    Plasma concentrations of RO7126209 were measured by a specific and validated assay at specified timepoints. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Day 1

  2. Area Under the Plasma Concentration Versus Time Curve From Zero to 24 h Postdose (AUC0-24h) of RO7126209

    Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Days 1 and 2

  3. Area Under the Plasma Concentration Versus Time Curve From Zero to 168h Postdose (AUC0-168h) of RO7126209

    Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Days 1, 2, 3, 4, 5 and 8

  4. Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO7126209

    Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57

  5. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)

    Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57

  6. Terminal Rate Constant (Lambda z) of RO7126209

    Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57

  7. Apparent Terminal Half-Life (T1/2) of RO7126209

    Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57

  8. Total Body Clearance Calculated as Dose/AUC (CL) of RO7126209

    Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57

  9. Volume of Distribution at Steady-State (Vss) of RO7126209

    Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57

  10. Cerebrospinal Fluid (CSF) Concentration of RO7126209

    RO7126209 CSF concentrations were measured by a specific and validated method. Geometric Mean and Coefficient of Variation data are presented below.

    Time frame: Day 3 and Day 5

  11. Percentage of Participants With Anti-RO7126209 Antibodies (ADAs)

    The numbers and proportions of Anti-Drug Antibody (ADA) positive participants and ADA negative participants at baseline (baseline prevalence) and after study drug administration (post-baseline incidence during both the treatment and follow-up periods) were summarized per dose group during both the treatment and follow-up period.

    Time frame: Days 1, 8, 29 and 57

07

Results

Posted Aug 9, 2021

Participant flow

The study was conducted at 1 center in 1 country.

Participant flow — Overall Study
MilestonePlaceboRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Started1044666
Completed1032566
Not completed012100
Withdrew: Lost to follow-up012000
Withdrew: Withdrawal by subject000100

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs)

An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.

Time frame:
Up to approximately 9 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsPlaceboRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Percentage of Participants With Adverse Events (AEs)80.075.050.083.3100.0100.0
SecondaryConcentration at the End of Infusion (Cend) of RO7126209

Plasma concentrations of RO7126209 were measured by a specific and validated assay at specified timepoints. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Day 1
Reported as:
Geometric mean · µg/mL
Concentration at the End of Infusion (Cend) of RO7126209
µg/mLRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Concentration at the End of Infusion (Cend) of RO71262091.80 ± 15.97.93 ± 21.322.2 ± 17.685.7 ± 22.9160 ± 26.5
SecondaryArea Under the Plasma Concentration Versus Time Curve From Zero to 24 h Postdose (AUC0-24h) of RO7126209

Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Days 1 and 2
Reported as:
Geometric mean · hr.µg/mL
Area Under the Plasma Concentration Versus Time Curve From Zero to 24 h Postdose (AUC0-24h) of RO7126209
hr.µg/mLRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Area Under the Plasma Concentration Versus Time Curve From Zero to 24 h Postdose (AUC0-24h) of RO712620927.1 ± 23.2124 ± 13.3325 ± 27.11170 ± 13.32340 ± 16.5
SecondaryArea Under the Plasma Concentration Versus Time Curve From Zero to 168h Postdose (AUC0-168h) of RO7126209

Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Days 1, 2, 3, 4, 5 and 8
Reported as:
Geometric mean · hr.µg/mL
Area Under the Plasma Concentration Versus Time Curve From Zero to 168h Postdose (AUC0-168h) of RO7126209
hr.µg/mLRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Area Under the Plasma Concentration Versus Time Curve From Zero to 168h Postdose (AUC0-168h) of RO712620978.0 ± 22.5350 ± 14.2807 ± 28.52940 ± 11.66190 ± 13.1
SecondaryArea Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO7126209

Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Reported as:
Geometric mean · hr.µg/mL
Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO7126209
hr.µg/mLRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Measurable Concentration (AUC0-last) of RO712620986.9 ± 21.9402 ± 14.4933 ± 30.73380 ± 11.57070 ± 10.9
SecondaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)

Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Reported as:
Geometric mean · hr.µg/mL
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)
hr.µg/mLRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)89.1 ± 21.7417 ± 13.7947 ± 29.33380 ± 11.57080 ± 10.9
SecondaryTerminal Rate Constant (Lambda z) of RO7126209

Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Reported as:
Geometric mean · (1/h)
Terminal Rate Constant (Lambda z) of RO7126209
(1/h)RO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Terminal Rate Constant (Lambda z) of RO71262090.0103 ± 19.70.00625 ± 57.00.00690 ± 59.00.00409 ± 19.50.00436 ± 21.8
SecondaryApparent Terminal Half-Life (T1/2) of RO7126209

Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Reported as:
Geometric mean · hr
Apparent Terminal Half-Life (T1/2) of RO7126209
hrRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Apparent Terminal Half-Life (T1/2) of RO712620967.1 ± 19.7111 ± 57.0100 ± 59.0170 ± 19.5159 ± 21.8
SecondaryTotal Body Clearance Calculated as Dose/AUC (CL) of RO7126209

Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Reported as:
Geometric mean · mL/hr/kg
Total Body Clearance Calculated as Dose/AUC (CL) of RO7126209
mL/hr/kgRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Total Body Clearance Calculated as Dose/AUC (CL) of RO71262091.14 ± 21.30.965 ± 13.81.28 ± 29.41.07 ± 10.91.03 ± 11.1
SecondaryVolume of Distribution at Steady-State (Vss) of RO7126209

Plasma concentrations of RO7126209 were measured by a specific and validated assay. Plasma PK parameters of RO7126209 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Days 1, 2, 3, 4, 5, 8, 10, 15, 22, 29, 43 and 57
Reported as:
Geometric mean · mL/kg
Volume of Distribution at Steady-State (Vss) of RO7126209
mL/kgRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Volume of Distribution at Steady-State (Vss) of RO712620988.6 ± 25.190.3 ± 26.3108 ± 35.588.7 ± 22.685.3 ± 22.8
SecondaryCerebrospinal Fluid (CSF) Concentration of RO7126209

RO7126209 CSF concentrations were measured by a specific and validated method. Geometric Mean and Coefficient of Variation data are presented below.

Time frame:
Day 3 and Day 5
Reported as:
Geometric mean · µg/mL
Cerebrospinal Fluid (CSF) Concentration of RO7126209
µg/mLRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Day 30.00414 ± 33.00.0202 ± 26.50.047 ± 29.40.105 ± 40.30.284 ± 35.9
Day 50.00228 ± 18.70.0126 ± 26.10.0274 ± 22.90.0755 ± 7.40.151 ± 9.8
SecondaryPercentage of Participants With Anti-RO7126209 Antibodies (ADAs)

The numbers and proportions of Anti-Drug Antibody (ADA) positive participants and ADA negative participants at baseline (baseline prevalence) and after study drug administration (post-baseline incidence during both the treatment and follow-up periods) were summarized per dose group during both the treatment and follow-up period.

Time frame:
Days 1, 8, 29 and 57
Reported as:
Number · Percentage of Participants
Percentage of Participants With Anti-RO7126209 Antibodies (ADAs)
Percentage of ParticipantsRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Percentage of Participants With Anti-RO7126209 Antibodies (ADAs)50.025.066.783.383.3

Adverse events

Collected over Up to approximately 9 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/10 (0%)0/10 (0%)8/10 (80%)
RO7126209 (0.1 mg/kg)0/4 (0%)0/4 (0%)3/4 (75%)
RO7126209 (0.4 mg/kg)0/4 (0%)0/4 (0%)2/4 (50%)
RO7126209 (1.2 mg/kg)0/6 (0%)0/6 (0%)5/6 (83.3%)
RO7126209 (3.6 mg/kg)0/6 (0%)0/6 (0%)6/6 (100%)
RO7126209 (7.2 mg/kg)0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)
Infusion related reactionInjury, poisoning and procedural complications1/100/40/40/65/66/6
HeadacheNervous system disorders5/100/41/45/61/63/6
Back painMusculoskeletal and connective tissue disorders0/103/41/43/61/60/6
NauseaGastrointestinal disorders3/100/40/43/62/60/6
VomitingGastrointestinal disorders2/100/40/41/61/60/6
Upper respiratory tract infectionInfections and infestations2/100/40/40/61/60/6
ChillsGeneral disorders0/100/40/40/61/60/6
Injection site extravasationGeneral disorders0/100/40/40/60/61/6
ParaesthesiaNervous system disorders1/100/40/41/61/60/6
PhlebitisVascular disorders0/100/40/40/60/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)Total
Mean29.2 ± 6.630.8 ± 5.923.5 ± 4.524.2 ± 3.833.0 ± 5.933.3 ± 2.629.2 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)Total
Female0000000
Male104466636
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)Total
Hispanic or Latino0000123
Not Hispanic or Latino104465433
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRO7126209 (0.1 mg/kg)RO7126209 (0.4 mg/kg)RO7126209 (1.2 mg/kg)RO7126209 (3.6 mg/kg)RO7126209 (7.2 mg/kg)Total
American Indian or Alaska Native0001001
Asian2000103
Black or African American31332113
White52113416
Multiple0101013
08

Study locations

1 site
  • PRA Health Sciences
    Raleigh, North Carolina 27612, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jul 2020, 11 months.

Results were first posted in Aug 2021, 1 year after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 11 months is close to that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Jul 18, 2019
StartActual
Aug 3, 2019
Primary completionActual
Jul 17, 2020
CompletionActual
Jul 17, 2020
Results first posted
Aug 9, 2021
Last update
Aug 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04023994
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 18, 2019
Start date
Aug 3, 2019
Primary completion
Jul 17, 2020
Completion
Jul 17, 2020
Results posted
Aug 9, 2021
Last update
Aug 9, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trontinemab

Start the discussion